Les criteres de jugement dans les essais cliniques: reflexions a propos d'etudes recentes de prevention cardio-vasculaire.

Scheen, André

Article (Scientific journals)

Scheen, André

2006 • In Revue Médicale de Liège, 61 (4), p. 260-6

Peer reviewed

Permalink
https://hdl.handle.net/2268/9470

PubMed
16789615

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

200604_13.pdf

Publisher postprint (462.71 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Cardiovascular Diseases/prevention & control; Clinical Trials as Topic; Evidence-Based Medicine; Humans; Risk Factors

Abstract :

[en] The comparison of two therapeutic interventions requires the use of endpoints in randomized clinical trials, which supports evidence-based medicine. It is preferable to consider hard endpoints, such as major clinical events and mortality rather than biological or surrogate endpoints. In large cardiovascular prevention trials, it is now well accepted to analyze primary and secondary endpoints as well as to use combined clinical endpoints. Such composite endpoints offer the advantage of increasing the number of events, but have the disadvantage of diluting the therapeutic effect and of exposing to possible bias. We discuss this crucial issue at the light of controversial results from a few recent important cardiovascular prevention trials.

Disciplines :

Cardiovascular & respiratory systems

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques - Médecine interne générale

Language :

French

Title :

Les criteres de jugement dans les essais cliniques: reflexions a propos d'etudes recentes de prevention cardio-vasculaire.

Alternative titles :

[en] How I explore...outcomes in clinical trials: comments about recent studies of cardiovascular prevention

Publication date :

2006

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

Issue :

Pages :

260-6

Peer reviewed :

Peer reviewed

Additional URL :

http://www.rmlg.ulg.ac.be

Available on ORBi :

since 23 March 2009

Statistics

Number of views

698 (0 by ULiège)

Number of downloads

1032 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenAlex citations

Bibliography

Scheen AJ.- Evidence-based medicine. Apport des essais cliniques contrôlés. Rev Med Liège, 2000, 55, 216-219.
Delvenne C, Pasleau F.- Comment résoudre en pratique un problème diagnostique ou thérapeutique en suivant une démarche EBM? Rev Med Liège, 2000, 55, 226-232.
Van den Bruel A, Chevalier P, Vermeire E, et al.- Evidence-Based Medicine. Otite moyenne chez l'enfant. Comment formuler une question PICO? Rev Med Liège, 2004, 59, 671-675.
Scheen AJ.- La mesure de l'efficacité thérapeutique, étape essentielle dans la médecine factuelle. Rev Med Liège, 2000, 55, 206-210.
Kuller LH.- Clinical trials: surrogate endpoints or hard endpoints? Am J Cardiol, 2001, 88 (suppl), 59E-61E.
LaRosa JC, Grundy SM, Waters DD, et al.- Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005, 352, 1425-1435.
Pedersen TR, Faergeman O, Kastelein JJP, et al. The Increment Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.- High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA, 2005, 294, 2437-2445.
The FIELD study investigators.- Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet, 2005, 366, 1849-1861.
Dahlöf G, Sever P, Poulter N, et al.- Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes trials: Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet, 2005, 366, 895-906.
Dormandy J, Charbonnel B, Eckland DJA, et al, on behalf of the PROactive investigators.- Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitA-zone Clinical Trial In macro Vascular Events): a randomised controlled trial. Lancet, 2005, 366, 1279-1289.
Scheen AJ.- Treating to New Targets: plaidoyer pour une valeur cible de cholestérol LDL égale ou inférieure à 75 mg/dl chez tout patient coronarien. Rev Med Liège, 2005, 60, 264-267.
Scheen AJ.- L'étude IDEAL comparant simvastatine 20-40 mg versus atorvastatine 80 mg en prévention après un infarctus du myocarde: entre deux idées de l'idéal. Rev Med Liège, 2006, 61, 53-59.
Radermecker RP, Scheen AJ.- L'étude FIELD de protection cardio-vasculaire avec le fénofibrate chez le patient diabétique de type 2. Rev Med Liège, 2005, 60, 957-961.
Krzesinski JM.- Première démonstration d'une supériorité des agents antihypertenseurs modernes par rapport aux molécules plus anciennes dans la prévention cardio-vasculaire: résultats du bras "abaissement de pression artérielle" de l'étude ASCOT. Rev Med Liège, 2005, 60, 820-826.
Scheen AJ, Lefèbvre PJ.- L'étude PROactive: prévention secondaire des accidents cardio-vasculaires par la pioglitazone chez le patient diabétique de type 2. Rev Med Liège, 2005, 60, 896-901.
Freemantle N.- Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? BMJ, 2001, 322, 989-991.
Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C.- Composite outcomes in randomized trials. Greater precision but with greater uncertainty? JAMA, 2003, 289, 2554-2559.
Nissen SE, Nicholls SJ, Sipahi I, et al.- Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID trial. JAMA, 2006, 95, online March 13 (doi:10.1001/jama.295.13.jpc60002).
Taylor A, Shaw LJ, Fayad Z, et al.- Tracking atherosclerosis regression: a clinical tool in preventive cardiology. Atherosclerosis, 2005, 180, 1-10.
Julius S, Kjeldsen SE. Weber M for the VALUE trial group.- Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004, 363, 2022-2031.
The FIELD Study Investigators.- The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Cardiovascular. Diabetohgy, 2004, 3, 9 (doi:10.1186:1475-2840-3-9).
Yki-Järvinen H.- The PROactive study: some answers, many questions (Editorial). Lancet, 2005, 366, 1241-1242.
Freemantle N.- How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events? BMJ, 2005, 331, 836-838.
Cannon CP, Braunwald E, McCabe CH, et al.- Comparison of intensive and moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med, 2004, 350, 1495-1504.
Cannon CP.- The IDEAL cholesterol. Lower is better (Editorial). JAMA, 2005, 294, 2492-2494.
Scheen AJ.- Interruption prématurée des études ASCOT et CARDS de prévention cardio-vasculaire avec l'atorvastatine chez le sujet hypertendu ou diabétique: compromis entre éthique et statistique en médecine factuelle. Rev Med Liège, 2003, 58, 585-590.
Pfeffer MA, Swedberg K, Granger CB, et al.- Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 2003, 362, 759-766.
Kulbertus H.- L'étude CHARM. Rev Med Liège, 2003, 58, 646-652.
Lubsen J, Kirwan BA.- Combined endpoints: can we use them? Stat Med, 2002, 21, 2959-2970.